Weekly Top News – Psoriasis – June 1, 2020

June 1, 2020

IMU-935 / Immunic
IMU-935: Initiation of PART B of P1 trial in healthy volunteers in Q3 2020 (Immunic Therapeutics) – May 28, 2020 – R&D Day: Initiation of PART C of P1 trial for moderate-to-severe psoriasis in H2 2020 
[Screenshot]

 

llllllllll brepocitinib (PF-06700841) / Pfizer
A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis (clinicaltrials.gov) – May 26, 2020 – P2b; N=218; Active, not recruiting; Sponsor: Pfizer; Recruiting –> Active, not recruiting

 

IMU-935 / Immunic
IMU-935: PK data from P1 trial for healthy volunteers in Q2 2020 (Immunic Therapeutics) – May 29, 2020 – Company Overview: Data from SAD and MAD parts of P1 trial for healthy volunteers later in 2020 
[Screenshot]

 

IMU-935 / Immunic
IMU-935: Data from PART C of P1 trial for psoriasis in 2021 (Immunic Therapeutics) – May 29, 2020 – R&D Day 
[Screenshot]

 

Siliq (brodalumab) / Bausch Health, LEO Pharma, Kyowa Hakko Kirin; Stelara (ustekinumab) / J&J
EMBRACE 1: Efficacy and Safety of Brodalumab in Adolescents From 12 to 17 Years of Age With Moderate-to-severe Plaque Psoriasis (clinicaltrials.gov) – May 28, 2020 – P3; N=120; Not yet recruiting; Sponsor: LEO Pharma; Trial completion date: Aug 2023 –> Nov 2023; Initiation date: Jun 2020 –> Sep 2020; Trial primary completion date: Oct 2022 –> Jan 2023

No Comments

Post a Comment

Comment
Name
Email
Website